MAL-di-EG-Val-Cit-PAB-MMAF
MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) [1].
Product Specifications
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mal-di-eg-val-cit-pab-mmaf.html
Purity
98.56
Solubility
DMSO : 230 mg/mL (ultrasonic)
Smiles
CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(N2[C@@H](CCC2)[C@@H]([C@@H](C)C(N[C@H](C(O)=O)CC3=CC=CC=C3)=O)OC)=O)OC)=O)=O)=O)C=C1)=O)=O)NC(CCOCCOCCNC(CCN4C(C=CC4=O)=O)=O)=O
Molecular Formula
C72H110N12O19
Molecular Weight
1447.71
References & Citations
[1]McCombs JR, et al. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015 Mar;17 (2) :339-51.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Auristatin
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog